Pfizer to exit GSK's consumer health arm after spin-off

Brasil Notícia Notícia

Pfizer to exit GSK's consumer health arm after spin-off
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 Reuters
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 97%

Pfizer plans to exit its 32% stake in Haleon, its consumer health joint venture with British drugmaker GSK , after the business is spun off as an independent listed company in July, GSK said on Wednesday.

Pfizer previously signalled it would seek to sell its shareholding in Haleon, which is home to Sensodyne toothpaste and Advil painkillers, but GSK said in February that the U.S. drugmaker would retain its stake.Register now for FREE unlimited access to Reuters.comGSK said it had applied to Britain's regulator to list Haleon on the London Stock Exchange on July 18 and would apply to list it on the New York Stock Exchange shortly.

Before the spinoff, the holding company for the consumer health business will pay dividends to GSK and Pfizer. That will translate to GSK receiving cash proceeds of more than 7 billion pounds at separation, GSK said. GSK, which will retain its focus on pharmaceuticals and vaccines, now has a 68% controlling interest Haleon.

Following the demerger, at least 54.5% of the total issued ordinary share capital of Haleon will be held by GSK shareholders, while up to 6% will be held by GSK, the British drugmaker said.Reporting by Natalie Grover in London and Ludwig Burger in Frankfurt; Twitter @NatalieGrover; Editing by Josephine MasonSign up to our investor newsletter to get the latest news and trends in global financial markets.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Reuters /  🏆 2. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

GSK Bolsters Vaccine Business With $3.3 Billion Deal for AffinivaxGSK Bolsters Vaccine Business With $3.3 Billion Deal for AffinivaxThe British pharmaceutical giant agreed to acquire the vaccine maker in a deal that would hand it a new vaccine technology targeting common bacterial diseases such as meningitis and pneumonia.
Consulte Mais informação »

GSK Buys Vaccine Developer Affinivax in $3.3 Billion DealGSK Buys Vaccine Developer Affinivax in $3.3 Billion DealAffinivax's latest vaccine fights pneumonia, meningitis, and bloodstream infections.
Consulte Mais informação »

Animated Film ‘Yourland’ Spins Off Game – C&E Europe News in BriefAnimated Film ‘Yourland’ Spins Off Game – C&E Europe News in BriefA few days before the premiere of Peter Budinský’s animated film “Yourland,” Nohavmede has launched the game “Yourland: Bowlers Run” to underscore the environmental themes of the film, in the lates…
Consulte Mais informação »

Universal Music Group Gets First Credit Ratings Since Going PublicUniversal Music Group Gets First Credit Ratings Since Going PublicUniversal Music Group received two strong ratings by credit ratings agencies on Tuesday, the company’s first as a stand-alone company since spinning off from Vivendi last September.
Consulte Mais informação »

Paxlovid Becomes Household Name for Covid-19 PatientsPaxlovid Becomes Household Name for Covid-19 PatientsPfizer’s antiviral drug sees an uptick in prescriptions, as more doctors order patients take it over the Merck-Ridgeback pill called Lagevrio.
Consulte Mais informação »



Render Time: 2025-03-01 13:05:44